Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Colorectal Neoplasms 8Neoplasms 2NSCLC 2Colonic Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rectal Neoplasms 1Osteosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Bone Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

osimertinib 2Vinorelbine 2Pemetrexed 2Liquid Biopsy 2HMPL-013 2Gefitinib 2Carboplatin 2tislelizumab 1sulindac sulfone 1rezivertinib 1pembrolizumab 1anlotinib 1Radiotherapy 1Platinum 1Paclitaxel 1Gemcitabine 1Cisplatin 1Cetuximab 1CP protocol 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × NSCLC × HMPL-013 × Clear all
NCT02976116 2019-11-15

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Hutchmed

Phase 2 Completed
50 enrolled
Thoracic

NSCLC

NCT02691299 2019-02-12

FALUCA

Hutchmed

Phase 3 Completed
527 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡